420 with CNW – Israeli Researchers Look into Treating Endometriosis Using Cannabis

November 20, 2018 04:20:13

Gynica, a startup in Israel, has announced that it will conduct research in order to find a new cannabis-based treatment for endometriosis. The startup will use the newly licensed Lumir Lab found within Hebrew University in Jerusalem for this research.

Gynica specializes in providing marijuana-based solutions to the problems affecting the health of women. The lab will focus on medical cannabis research and product development.

Lumir Lab is headed by Lumir Odrej Hanus, one of the leading researchers on cannabinoids in the world. He is an analytical chemist.

Lumir Lab will collaborate with Gynica in this quest for a treatment for endometriosis. Endometriosis is a health condition in which tissues from the lining of the uterus migrate to other parts of the body. The condition causes a lot of pain among its estimated 180 million sufferers across the world.

Current research shows that the reproductive system of females is the second to the brain in terms of having the biggest number of endocannabinoid receptors within the body.

This reality creates an opportunity for cannabis to be used to influence the reproductive system so that uterine lining tissues reduce or stop moving from the uterus to the other internal organs of affected females.

The planned research by Gynica and Lumir Lab is intended to understand how cannabis works to alleviate the symptoms of endometriosis, or even stop the tissues from migrating. The research will also try to find the specific cannabinoids that give the greatest effects in preventing tissue migration or curbing disease recurrence in a way that leaves the ovulation cycle intact.

In the long run, the lab plans to set the standard by which cannabis research and product development is done around the world. Such research will help to address the concerns and reservations within the scientific community regarding cannabis as a treatment for various health conditions.

Currently, many of the cannabis treatments available are largely based on evidence that may not stand up to strict scientific scrutiny. Lumir Lab wants to end all this by bringing clinical analysis, validation and product development to the medical cannabis field. Terpene and cannabinoid profiling will also be done at the lab.

It is this type of research that will make cannabis treatments mainstream since no one will be able to claim that they don’t have any scientific backing behind them. Cannabis industry companies like Net Element (NASDAQ: NETE) and NUGL Inc. (OTC: NUGL) welcome every attempt to gather evidence in support of the different uses of cannabis, including the new efforts launched in Israel by Lumir Lab and Gynica.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office